Mrl mp

Eight-week old non-obese diabetic (NOD), FVB/nj (WT), MRL/Mp and MRL/MpJ-Fas^lpr (referred to as MRL/Mp-Fas all along) female mice were obtained from The Jackson Laboratory. All protocols used with the mice have been approved by the NIH animal use committee (ASP 16-799). The NOD mice were housed under controlled temperature and 12 hrs dark/light cycles with free access to water and food. Twelve weeks old female MRL/Mp and part of the MRL/Mp-Fas mice were treated with Poly IC exactly as described^{27 (link)} to induce AIP. Treatment with C18 started one month after start of treatment with Poly IC that continued during the two weeks treatment with C18. Twelve weeks old NOD mice were treated with VX770 (Sigma) or C18 (1-(benzo[d][1,3]dioxol-5-yl)-N-(5-((S)-(2-chlorophenyl)((R)-3-hydroxypyrrolidin-1-yl)methyl)thiazol-2-yl)cyclopropanecarboxamide). C18 was obtained from the CFFT modulator panel distributed by Rosalind Franklin University. C18 was synthesized by Exclusive Chemistry LTD (Obninski, Russia) as in Vertex patent WO2007/021982A2. Treatment with C18 and VX770 was by daily I.P. injection of 2 mg/kg dissolved in DMSO in a volume of 50 μl. At the end of treatments mice were sacrificed and the pancreas, parotid, and submandibular glands were removed for analysis.